Canaccord Genuity Group Has Lowered Expectations for Organigram (TSE:OGI) Stock Price

Organigram (TSE:OGI) had its price objective decreased by equities research analysts at Canaccord Genuity Group from C$3.60 to C$3.15 in a research report issued to clients and investors on Monday,BayStreet.CA reports. The firm currently has a “speculative buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 45.16% from the company’s current price.

Organigram Price Performance

Shares of TSE OGI opened at C$2.17 on Monday. Organigram has a fifty-two week low of C$1.61 and a fifty-two week high of C$3.95. The firm’s 50-day simple moving average is C$2.29 and its 200 day simple moving average is C$2.32. The company has a quick ratio of 2.62, a current ratio of 6.95 and a debt-to-equity ratio of 1.13. The stock has a market cap of C$235.60 million, a P/E ratio of -0.87, a P/E/G ratio of 0.42 and a beta of 1.13.

Insider Activity at Organigram

In related news, Senior Officer Paolo De Luca sold 12,014 shares of Organigram stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of C$2.52, for a total value of C$30,275.28. Company insiders own 31.32% of the company’s stock.

Organigram Company Profile

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.